Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4

Diabetes

Volumn 53, Issue 7, 2004, Pages 1700-1705

  Ogawa, Norihiko ^a   List, James F ^b   Habener, Joel F ^b   Maki, Takashi ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GROWTH FACTOR; INSULIN; LYMPHOCYTE ANTIBODY; POLYCLONAL ANTIBODY; T LYMPHOCYTE ANTIBODY;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CELL DIFFERENTIATION; CELL DIVISION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENTIATION; FEMALE; GLUCOSE TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; LYMPHOCYTE TRANSFER; MOUSE; MOUSE STRAIN; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ANIMALS; ANTILYMPHOCYTE SERUM; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE AGENTS; INSULIN; MICE; MICE, INBRED NOD; MICE, SCID; PANCREAS; PANCREAS TRANSPLANTATION; PEPTIDES; VENOMS;

EID: 3042737844     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.53.7.1700     Document Type: Article

References (34)

1. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y: Breeding of a nonobese diabetic strain of mice. Exp Animal 29:1-13, 1980
2. Cahill GF, McDevitt HO: Insulin-dependent diabetes mellitus: the initial lesion. N Engl J Med 304:1454-1465, 1981
3. Gorsuch AN, Spencer KM, Lister J, McNally JM, Dean BM, Tottazzo GF, Cudworth AG: Evidence for a long prediabetic period in type 1 (insulin-dependent) diabetes mellitus. Lancet 2:1363-1365, 1981
4. Harada M, Makino S: Suppression of overt diabetes in NOD mice by anti-thymocyte serum or anti-Thy 1.2 antibody. Exp Animals 35:501-504, 1986
5. Koike T, Ito Y, Ishii T, Itoh Y, Takabayashi K, Maruyama N, Tomioka H, Yosida S: Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes 36:539-541, 1987
6. Charlton B, Bacelj A, Mandel TE: Administration of silica particles or anti-Lyt2 antibody prevents β-cell destruction in NOD mice given cyclophosphamide. Diabetes 37:930-935, 1988
7. Maki T, Ichikawa T, Blanco R, Porter J: Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc Natl Acad Sci U S A 89:3434-3438, 1992
8. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 (7-36) amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
9. Thorens B, Porret A, Buhler L, Deng S-P, Morel P, Widmann C: Cloning and functional expression of the human islet GLP-1 receptor: demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682, 1993
10. Chen YE, Drucker DJ: Tissue-specific expression of unique mRNA that encode pro-glucagon-derived peptides or exendin 4 in the lizard. J Bio Chem 272:4018-4115, 1997
11. Goke R, Fehmann HC, Linn T, Schmidt J, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagons-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268:19650-19655, 1993
12. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S: Antidiabetogenic effect of glucagon-like peptide 1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322, 1992
13. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-1(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
14. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucgon-like peptide 1(7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744, 1993
15. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR: Glucagon-like peptide-1(GLP-1): a trial in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27:533-536, 1997
16. Xu G, Stoffers AD, Habener FJ, Bonner-Weir S: Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276, 1999
17. Tourrel C, Bailbe D, Meile M-J, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-1570, 2001
18. Zhou J, Wang X, Pineyro MA, Egan JM: Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358-2366, 1999
19. Monaco AP, Wood ML: Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc 2:489-492, 1970
20. Thomas MK, Rastalsky N, Lee JH, Habener JF: Hedgehog signaling regulation of insulin production by pancreatic β-cells. Diabetes 49:2039-2047, 2000
21. Pastorale C, Arata M, Caminos A, Bruno L, Basabe J, Chemes H: Effect of modified diabetic splenocytes on mice injected with multiple low-dose streptozotocin. Exp Biol Med 227:282-289, 2002
22. Stoffers DA, Kieffer TJ, Hussain MA, Drucker DJ, Bonner-Weir S, Habener JF, Egan JM: Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49:741-748, 2000
23. Hui H, Wright C, Perfetti R: Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50:785-796, 2001
24. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478, 2003
25. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL: Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302:1223-1227, 2003
26. Zorina TD, Subbotin VM, Bertera S, Alexander AM, Haluszczak C, Gambrell B, Bottino R, Styche AJ, Trucco M: Recovery of the endogenous beta cell function in the NOD model of autoimmune diabetes. Stem Cells 21:377-388, 2003
27. Hess D, Li L, Martin M, Sakano S, Hill D, Strutt B, Thyssen S, Gray DA, Bhatia M: Bone marrow-derived stem cells initiate pancreatic regeneration. Nat Biotechnol 21:763-770, 2003
28. Movassat J, Beattie GM, Lopez AD, Hayek A: Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. J Clin Endocrinol Metab 87:4775-4781, 2002
29. Hardikar AA, Wang XY, Williams LJ, Kwok J, Wong R, Yao M, Tuch BE: Functional maturation of fetal porcine b-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 143:3505-3514, 2002
30. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408, 2002
31. Chatenoud L, Thervet E, Primo J, Bach JF: Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 91:123-127, 1994
32. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin R, Bluestone JA: Anti-CD3 monoclonal antibody in new onset type 1 diabetes mellitus. N Engl J Med 346:1692-1697, 2002
33. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, Kim D, Baron AD: Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377, 2003
34. Amylin Pharmaceuticals: Exenatide: (synthetic exendin-4) [article online], 2003. Available from http://www.amylin.com/Pipeline/AC2993.cfm. Accessed 10 December 2003